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Abstract
The objective of this study was to validate the use of pftetQ and
pfmdt genes as molecular markers of decreased in vitro suscepti-
bility to doxycycline in 113 Plasmodium falciparum isolates from
Dakar, Senegal. The results show that copy numbers of pftetQ
and pfmdt, estimated by TaqMan real-time PCR, are not signifi-
cantly associated with reduced susceptibility to doxycycline
in vitro; however, the number of samples with a high doxycycline
IC50 was likely to be too low to derive statistically significant
results. Thus, no definitive conclusions could be drawn. The
markers should be further tested by analysing more isolates.
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Daily administration of doxycycline (DOX) is now one of
the recommended chemoprophylactic regimens for travellers
visiting malaria-endemic areas with high prevalence of resis-
tance to chloroquine or multidrug resistance [1]. In addition,
the French malaria consensus recommends quinine associ-
ated with DOX for Asian and South-American P. falciparum.
DOX remains recommended in the second-line treatment of
uncomplicated falciparum malaria or in the treatment of
severe malaria in combination with artesunate or quinine
for a 7-day course [2], but its use is limited. Prophylactic fail-
ure of DOX against P. falciparum has been associated with
inadequate doses [3] or poor compliance [4]. Failures with
prophylactic DOX could be also explained by resistance.
Our ability to maximize the efficacy and longevity of anti-
malarials as tools for malaria control will depend critically on
intensive research (to identify in vitro markers) and on in vitro
and in vivo surveillance programmes. It is necessary to iden-
tify molecular markers that predict DOX resistance so that
active surveillance can monitor temporal trends in parasite
susceptibility [5]. While no clinical failure in treating falcipa-
rum malaria with DOX has yet been reported, a Bayesian
mixture modelling approach has distinguished three different
in vitro phenotypic groups (low, medium and high DOX IC50)
among 747 P. falciparum isolates obtained from 14 African
countries over a 9-year period [6]. The sequences of 11
P. falciparum genes analogous to those involved in bacterial
resistance to DOX were obtained from 30 isolates from
each phenotypic group. Data suggested that copy numbers of
a tetQ GTPase family gene, pftetQ (PFL1710c), and a meta-
bolic drug transporter gene, pfmdt (PFE0825w), were poten-
tial molecular markers of decreased in vitro susceptibility to
DOX in African isolates [7].
The objective of this study was to validate the use of
pftetQ and pfmdt genes as molecular markers of decreased in
vitro susceptibility to DOX in field isolates from Dakar,
Senegal.
In total, 113 patients with malaria were recruited between
October 2009 and October 2010 at the Hoˆpital Principal de
Dakar and at Centre de Sante´ Elisabeth Diouf in Dakar.
Venous blood samples were collected in Vacutainer ACD
tubes (Becton Dickinson, Rutherford, NJ, USA) prior to
patient treatment; blood samples were used to test for drug
susceptibility within 24 h of collection.
Informed oral consent was obtained from patients and/or
their parents before blood collection. The study was
reviewed and approved by the ethical commission of Hoˆpital
Principal de Dakar.
Ex vivo testing of DOX susceptibility was performed as
previously described by a 42-h culture test revealed by the
Plasmodium lactate dehydrogenase (pLDH) ELISA method [8].
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pfmdt and pftetQ copy numbers were estimated by TaqMan
real-time PCR as previously described [7].
Data were analysed using R software (version 2.10.1.). Dif-
ferences in pfmdt and pftetQ copy numbers across pheno-
typic groups were tested using the Mann–Whitney U-test.
Genotype proportions were compared using the Fisher’s
exact test. The Spearman’s rank correlation coefficient (rho)
was evaluated between pfmdt and pftetQ copy numbers. Sta-
tistical differences were considered significant when p <0.05.
The IC50 values were distributed from 0.43 to 43.54 lM
(Fig. 1). Of the 113 Senegalese isolates, 18 (15.9%) belong to
the high-DOX-IC50 phenotype (IC50 > 25 lM). There was
no statistically significant difference between the group with
IC50 < 25 lM and the group with IC50 > 25 lM in terms of
the percentage of isolates with one or more copies of the
pftetQ gene (p 0.079, Fisher’s exact test) or pfmdt gene
(p 0.066, Fisher’s exact test) (Table 1).
No statistically significant difference was found between
DOX IC50 medians of isolates with one copy of the pftetQ
gene (mean = 14.41 lM) and more than one copy of the
gene (mean = 20.64 lM) (p 0.16, Mann–Whitney U-test)
(Table 2). Similarly, no statistically significant difference was
found between DOX IC50 medians of isolates with one copy
of the pfmdt gene (mean = 14.49 lM) and more than one
copy of the gene (mean = 26.04 lM) (p 0.30, Mann–Whitney
U-test) (Table 2). pfmdt and pftetQ copy numbers were signif-
icantly correlated (q = 0.30, CI 95% (0.19–0.40), Spearman’s
test, p <0.0001).
Most DOX prophylactic failures against P. falciparum are
associated with the use of standard doses that result in
lower-than-expected serum drug levels [9], inadequate doses
[3] or poor compliance [4,10]. Moreover, DOX pharmacoki-
netic parameters could explain some of these cases. DOX
has a short elimination half-life (16 h) and a short mean resi-
dence time (63% of the administered dose is eliminated in
27 h) [11]. In addition, its slow action in vitro has a delayed
effect upon growth and requires prolonged incubation of
parasites [12]. Determination of IC50 after two generations
of parasite growth decreases the 42-h IC50 by a factor from
10 to 20 [13,14]. However, in practice, the standard 42-h test
is still used to monitor DOX in vitro susceptibility surveil-
lance.
pftetQ is a tetQ GTPase-gene-family analogue of bacterial
ribosomal protection protein genes, which are involved in
bacterial resistance to cyclines. A metabolic drug transporter
gene, pfmdt, shares high sequence identity with efflux pumps.
In a multivariate logistic regression model, an increase in the
pfmdt copy number was associated with high DOX IC50,
with an adjusted odds ratio (OR) of 7.09 (p 0.011); similarly,
an increase in the pftetQ copy number was associated with
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FIG. 1. Distribution of the doxycycline IC50 for the 113 P. falciparum isolates.
TABLE 1. Statistical analysis of pftetQ and pfmdt copy num-
bers in 113 Senegalese isolates (Fisher’s exact test)
PftetQ Pfmdt
IC50 <
25 lM
IC50 >
25 lM
IC50 <
25 lM
IC50 >
25 lM
Copy number > 1 4 3 1 2
Copy number = 1 91 15 94 16
Percentage 4.40 20.00 1.06 12.50
Fisher’s exact test p value 0.0793 p value 0.0656
TABLE 2. Statistical analysis of pftetQ and pfmdt copy num-
bers in Senegalese isolates (Mann–Whitney U-test)
pftetQ pfmdt
Copy
number = 1
Copy
number > 1
Copy
number = 1
Copy
number > 1
Number of values 106 7 110 3
Minimum 0.43 5.57 0.43 6.72
25% percentile 8.72 10.43 8.935 6.72
Median 11.79 17.2 12.06 33.38
75% percentile 18.06 33.38 18.06 38.02
Maximum 43.54 38.02 43.54 38.02
Mean 14.41 20.64 14.49 26.04
Standard deviation 10.11 12.13 10 16.89
Standard error 0.9819 4.585 0.9538 9.752
Lower 95% CI of mean 12.46 9.421 12.6 )15.92
Upper 95% CI of mean 16.36 31.86 16.38 68
Mann–Whitney U-test p value 0.1617 p value 0.2961
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an adjusted OR of 5.23 (p 0.042) [7]. In this study, there was
no statistically significant difference between the group with
an IC50 < 25 lM and the group with an IC50 > 25 lM in
terms of the percentage of isolates with one or more copies
of the pftetQ gene (p 0.079) or of the pfmdt gene (p 0.066).
However, these data showed a tendency; the percentages of
pftetQ and pfmdt with more than one copy were higher in
the group with an IC50 > 25 lM (20% vs. 4.4% and 12.5% vs.
1.1%, respectively). The significance levels of these associa-
tions were just above the p-value threshold. These results
suggest that the number of isolates from the group with high
DOX IC50 (15.9%) was likely to be too low to yield statisti-
cally significant differences, thus showing the necessity of
using more isolates to assess gene copy numbers. Epidemio-
logical studies using large numbers of parasites with reduced
susceptibility to DOX are required if pftetQ and pfmdt are to
be used as markers of reduced in vitro DOX susceptibility.
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